Abbvie
Open
$227.29
Prev. Close
$227.41
High
$227.90
Low
$227.17
Market Snapshot
$402.67B
110.8
2.41
$56.33B
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. The company is headquartered in North Chicago, Illinois and currently employs 57,000 full-time employees. The company went IPO on 2013-01-02. The company is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its investigational candidate, bretisilocin, is for the treatment of patients with moderate-to-severe major depressive disorder (MDD).
NFJ Investment Group decreased its AbbVie stake despite the company's positive earnings report and growing interest from institutional investors in the biopharmaceutical sector.
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. The company is headquartered in North Chicago, Illinois and currently employs 57,000 full-time employees. The company went IPO on 2013-01-02. The company is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its investigational candidate, bretisilocin, is for the treatment of patients with moderate-to-severe major depressive disorder (MDD).
Recently from Cashu
AbbVie Set to Present Key Blood Cancer Treatment Results at EHA 2026 Congress
AbbVie Inc (Ticker: ABBV) is poised to present vital new results from its blood cancer treatment portfolio at the upcoming European Hematology Association (EHA) Congress in 2026. The company plans to…
AbbVie's Elahere Approved for Ovarian Cancer, Revolutionizing Treatment Options in Oncology
AbbVie (Ticker: ABBV) makes a significant stride in oncology with its ovarian cancer drug Elahere gaining approval from the NHS in England for treating advanced, platinum-resistant ovarian cancer. Thi…
AbbVie Gains EU Approval for AQUIPTA, Advancing Migraine Treatment Options for Patients.
AbbVie (Ticker: ABBV) secures a pivotal regulatory victory with the recent approval of AQUIPTA (atogepant) by the European Commission for acute migraine treatment in adults. This significant achieveme…
AbbVie Expands CLL Treatment Options with New VENCLYXTO Combination Therapies in Europe
AbbVie (Ticker: ABBV) announces an important expansion in its treatment options for patients diagnosed with chronic lymphocytic leukemia (CLL). The European Commission has authorized an updated label…